Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision –
– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart –
– Detailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024 –
– Vabysmo is approved in the U.S. for RVO, and in more than 90 countries around the world for people living with wet AMD and DME –